This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Jun 15;152(12):JC6-9.

doi: 10.7326/0003-4819-152-12-201006150-02009.

ACP Journal Club. Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk factors

No authors listed

PMID: 20547903
DOI: 10.7326/0003-4819-152-12-201006150-02009

Comment

ACP Journal Club. Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk factors

No authors listed. Ann Intern Med. 2010.

. 2010 Jun 15;152(12):JC6-9.

doi: 10.7326/0003-4819-152-12-201006150-02009.

PMID: 20547903
DOI: 10.7326/0003-4819-152-12-201006150-02009

No abstract available

PubMed Disclaimer

Comment on

Effect of valsartan on the incidence of diabetes and cardiovascular events.
NAVIGATOR Study Group; McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. NAVIGATOR Study Group, et al. N Engl J Med. 2010 Apr 22;362(16):1477-90. doi: 10.1056/NEJMoa1001121. Epub 2010 Mar 14. N Engl J Med. 2010. PMID: 20228403 Clinical Trial.

Similar articles

ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.
Farkouh M. Farkouh M. Ann Intern Med. 2010 Jun 15;152(12):JC6-10. doi: 10.7326/0003-4819-152-12-201006150-02010. Ann Intern Med. 2010. PMID: 20547892 No abstract available.
ACP Journal Club. Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes.
Lipscombe LL. Lipscombe LL. Ann Intern Med. 2009 Sep 15;151(6):JC3-6. doi: 10.7326/0003-4819-151-6-200909150-02006. Ann Intern Med. 2009. PMID: 19755352 No abstract available.
ACP journal club. Intensive glucose control increased mortality and did not prevent CV events compared with standard glucose control in type 2 diabetes.
Grubina R, Smith SA. Grubina R, et al. Ann Intern Med. 2011 May 17;154(10):JC5-02. doi: 10.7326/0003-4819-154-10-201105170-02002. Ann Intern Med. 2011. PMID: 21576520 No abstract available.
Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose.
DeFronzo RA, Abdul-Ghani M. DeFronzo RA, et al. Am J Cardiol. 2011 Aug 2;108(3 Suppl):3B-24B. doi: 10.1016/j.amjcard.2011.03.013. Am J Cardiol. 2011. PMID: 21802577 Review.
Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U. Zeymer U. Int J Cardiol. 2006 Feb 8;107(1):11-20. doi: 10.1016/j.ijcard.2005.02.033. Int J Cardiol. 2006. PMID: 16337493 Review.

See all similar articles

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Atypon